// App-Quantinova.ai

5515 : Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the Phase 1b KEYNOTE-028 study.

Researchers

Presenter

  • Jean-Sebastien Frenel

Principal Investigators

  • Christophe Le Tourneau

  • Bert H. O'Neil

  • Patrick Alexander Ott

  • Sarina Anne Piha-Paul

  • Carlos Alberto Gomez-Roca

  • Emilie Van Brummelen

  • Hope S. Rugo

  • Shari Thomas

  • Sanatan Saraf

  • Mei Chen

  • Andrea Varga

Medical Centers

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Institut Curie, Paris Cedex, France

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Dana-Farber Cancer Institute, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Institut Claudius Regaud, Toulouse, France

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • University of California, San Francisco, San Francisco, CA

  • Merck & Co., Inc., Kenilworth, NJ

  • Gustave Roussy, Villejuif, France

Locations

  • France

  • United States

  • Netherlands

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02054806

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved